Immuneering Corporation (IMRX)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
4.99 USD
-0.22
(-4.223%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.10 +0.11 (2.204%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:13 a.m. EDT
The investment case here is defined by a stark contradiction between a pristine balance sheet and a deteriorating business reality. Fundamentally, the company holds a fortress-like liquidity position with nearly $150 million in cash against negligible debt, providing ample runway to fund its pipeline without immediate dilution fears. However, the stock has suffered a catastrophic structural decline, dropping over 83% from its peak four years ago. While the most recent annual period saw a massive rebound, the underlying trajectory remains deeply concerning, with two of the last four years seeing double-digit percentage losses. This disconnect creates a speculative opportunity: the market is pricing in failure despite the cash pile, yet the lack of consistent revenue growth and negative returns on equity suggest the core business engine is struggling. The recent news of extended cash runways and trial updates provides a necessary floor, but until there is proof of commercial viability or sustained profitability, this remains a high-risk gamble on a turnaround rather than a solid investment in a thriving enterprise. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.224481 |
| AutoARIMA | 0.225712 |
| AutoETS | 0.226608 |
| AutoTheta | 0.273458 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.251 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.905 |
| Market Cap | 322,840,000 |
| Forward P/E | -3.87 |
| Beta | 0.37 |
| Website | https://immuneering.com |
As of Aug. 22, 2026, 5:13 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bet. Call Open Interest is heavily skewed toward out-of-the-money strikes (7.5 and 10.0), suggesting a hope for a massive biotech-style spike, while Put Open Interest concentrates at lower strikes (2.5 and 7.5), indicating a fear of a crash. The implied volatility is elevated across the board, reflecting uncertainty about whether the company can extend its cash runway or if clinical trial results will trigger a binary event.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.16694492 |
| Address1 | 245 Main Street |
| Address2 | Second Floor |
| All Time High | 33.99 |
| All Time Low | 1.0 |
| Ask | 5.52 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 547,200 |
| Average Daily Volume3 Month | 1,217,246 |
| Average Volume | 1,217,246 |
| Average Volume10Days | 547,200 |
| Beta | 0.368 |
| Bid | 3.22 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 2.948 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.99 |
| Current Ratio | 19.467 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.214 |
| Day Low | 4.935 |
| Debt To Equity | 1.905 |
| Display Name | Immuneering |
| Earnings Call Timestamp End | 1,762,808,400 |
| Earnings Call Timestamp Start | 1,762,808,400 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -63,119,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.797 |
| Enterprise Value | 176,573,328 |
| Eps Current Year | -1.1125 |
| Eps Forward | -1.29 |
| Eps Trailing Twelve Months | -0.89 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.8035 |
| Fifty Day Average Change | 0.1864996 |
| Fifty Day Average Change Percent | 0.03882577 |
| Fifty Two Week Change Percent | -16.694492 |
| Fifty Two Week High | 10.08 |
| Fifty Two Week High Change | -5.09 |
| Fifty Two Week High Change Percent | -0.50496036 |
| Fifty Two Week Low | 3.86 |
| Fifty Two Week Low Change | 1.1299999 |
| Fifty Two Week Low Change Percent | 0.2927461 |
| Fifty Two Week Range | 3.86 - 10.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 49,210,138 |
| Forward Eps | -1.29 |
| Forward P E | -3.868217 |
| Free Cashflow | -39,351,576 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 57 |
| Fullday Change | -0.22 |
| Fullday Change Percent | -4.22265 |
| Fullday Price | 5.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13824001 |
| Held Percent Institutions | 0.55608004 |
| Implied Shares Outstanding | 64,697,402 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Immuneering Corporation |
| Market | us_market |
| Market Cap | 322,840,000 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_308350677 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -57,276,208 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 338,367,412 |
| Number Of Analyst Opinions | 7 |
| Open | 5.21 |
| Operating Cashflow | -56,752,672 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 500 8080 |
| Post Market Change | 0.11000013 |
| Post Market Change Percent | 2.2044115 |
| Post Market Price | 5.1 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 5.21 |
| Price Eps Current Year | -4.485393 |
| Price Hint | 4 |
| Price To Book | 1.692673 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.471 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.22 |
| Regular Market Change Percent | -4.22265 |
| Regular Market Day High | 5.214 |
| Regular Market Day Low | 4.935 |
| Regular Market Day Range | 4.935 - 5.214 |
| Regular Market Open | 5.21 |
| Regular Market Previous Close | 5.21 |
| Regular Market Price | 4.99 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 793,043 |
| Return On Assets | -0.32768002 |
| Return On Equity | -0.52147 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,697,402 |
| Shares Percent Shares Out | 0.22299999 |
| Shares Short | 14,426,945 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 15,208,579 |
| Short Name | Immuneering Corporation |
| Short Percent Of Float | 0.29389998 |
| Short Ratio | 19.43 |
| Source Interval | 15 |
| State | MA |
| Symbol | IMRX |
| Target High Price | 30.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 17.57143 |
| Target Median Price | 17.0 |
| Total Cash | 149,900,320 |
| Total Cash Per Share | 2.317 |
| Total Debt | 3,633,607 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.89 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.2995 |
| Two Hundred Day Average Change | -0.30950022 |
| Two Hundred Day Average Change Percent | -0.05840178 |
| Type Disp | Equity |
| Volume | 793,043 |
| Website | https://immuneering.com |
| Zip | 2,142 |